Alvogen launches first generic equivalent of Zoladex

Complements a fast growing complex product pipeline in the region.

Reseligo contains the active ingredient goserelin and belongs to the class of GnRH agonists (analogues of gonadotropin releasing hormone) which interfere with the regulation of the sex hormone balance. As a consequence, testosterone levels are lowered in men and estradiol levels are lowered in women. This artificially induced lowering of hormone levels enables the symptomatic therapy of hormonesensitive tumours such as prostate cancer or breast cancer with goserelin. In addition, goserelin is used to treat certain benign gynecological disorders. Goserelin is administered in the form of a biodegradable implant which releases the active ingredient over a period of either one or 3 months.

Hacho Hatchikian, Executive Vice President at Alvogen in the CEE region, commented: "We are delighted about the launch of Reseligo. This product represents an important milestone in the further development of our oncology portfolio in the region. After already being on the market in the CEE region with three biosimilar products, this is yet another first-to-market complex product in our portfolio, which reaffirms Alvogen’s leadership position in delivering difficult-to-make but affordable treatments to patients. Reseligo offers a more affordable — but equally effective — treatment option for cancer patients, offering compelling cost saving opportunities within the Central and Eastern European region."